Ozempic & GLP-1 Lawsuit in Arkansas

GLP-1 receptor agonist medications — including Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, and Trulicity — were prescribed to millions of Arkansas residents for type 2 diabetes and weight management. While these drugs were marketed as breakthrough treatments, growing evidence has linked them to severe and sometimes permanent injuries that the manufacturers allegedly failed to adequately disclose.

The federal litigation against Novo Nordisk and Eli Lilly has been consolidated into multidistrict litigation (MDL 3094) in the Eastern District of Pennsylvania. Arkansas residents who suffered injuries from GLP-1 medications can file claims that join this consolidated proceeding, benefiting from coordinated pretrial discovery while retaining their individual right to trial.

The lawsuits allege that the manufacturers knew their drugs could cause serious gastrointestinal injuries — including stomach paralysis, bowel blockages, and pancreatic inflammation — as well as vision loss, yet they prioritized profits over patient safety by failing to warn prescribers and patients about the true scope of these risks. For Arkansas residents, the stakes are high: these injuries can be permanent, require multiple surgeries, and fundamentally alter quality of life.

As the litigation progresses, early bellwether trials are expected to set the stage for broader settlement discussions. Arkansas residents who have been injured should evaluate their claims now, before filing deadlines expire.

Arkansas legal landscape: Arkansas follows modified comparative fault with a 49% bar — a plaintiff who is 50% or more at fault cannot recover. The state applies strict liability for product defect claims and does not impose statutory caps on punitive damages in pharmaceutical cases. Residents in Little Rock, Fort Smith, Fayetteville, and Springdale and surrounding areas should consult with an attorney experienced in pharmaceutical litigation to evaluate their potential claim.